The smooth muscle cell membrane during atherogenesis: A potential target for amlodipine in atheroprotection

American Heart Journal

Volumn 141, Issue 2 SUPPL., 2001, Pages

  Tulenko, T N ^a,b   Sumner, A E ^c   Chen, M ^d   Huang, Y ^a,b   Laury Kleintop, L ^a,b   Ferdinand, F D ^a,b  

^a Lankenau Medical Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMLODIPINE; CALCIUM ANTAGONIST; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALCIUM TRANSPORT; CELL TRANSFORMATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; INFLAMMATORY CELL; MEMBRANE PERMEABILITY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SMOOTH MUSCLE FIBER MEMBRANE; VASCULAR SMOOTH MUSCLE;

EID: 0035147035     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.109947     Document Type: Conference Paper

References (89)

1. Vital statistics of the United States, 1990-1995
2. Cardiovascular disease myths and facts
3. Cholesterol in the prediction atherosclerotic disease. New perspectives based on The Framingham Study
4. High density lipoproteins: Epidemiologic profile and risks of coronary artery disease
5. Overall coronary heart disease mortality rate in relation to major risk factors in 325,348 men screened for the MRFIT
6. A receptor-mediated pathway for cholesterol homeostasis
7. Lessons from cholesterol-lowering trials
8. Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association
9. Cardiovascular medicine at the turn of the millennium: Triumphs, concerns and opportunities
10. The pathogenesis of atherosclerosis
11. Atherosclerosis: A problem of the biology of arterial wall cells and their interactions with blood components
12. The pathogenesis of atherosclerosis: An update
13. Pathogenesis of atherosclerosis: A perspective for the 1990s
14. Atherosclerosis: A defense mechanism gone awry
15. Cell biology of atherosclerosis
16. Atherosclerosis: An inflammatory disease
17. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation
18. The role of macrophages in atherogenesis
19. Cytokines as modulators of cell proliferation in fibrotic diseases
20. Development of the smooth muscle foam cell: Uptake of macrophage lipid inclusions
21. Smooth muscle phenotypic changes in arterial wall homeostasis: Implications for the pathogenesis of atherosclerosis
22. Phenotypic modulation of smooth muscle cells in culture
23. Plasma LDL accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycan composition
24. Proteoglycans and lipoproreins in atherosclerosis
25. The interaction of low density lipoproteins with arterial proteoglycans
26. Collagenous proteins of blood vessels
27. The pathogenesis of atherosclerosis: Atherogenesis and inflammation
28. Beyond cholesterol: Modifications of low-density lipoprotein that increase its otherogenicity
29. Oxidized LDL-induced leukocyte/endothelium interaction in viva involves the receptor for platelet-activating factor
30. Oxidized low density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation: Role of P-selectin
31. Lipoprotein metabolism in the macrophage
32. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells
33. Inhibition of hypercholesterolemia-induced atherosderosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
34. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit LDL protein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit
35. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue that does not lower serum cholesterol
36. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits
37. Antioxidants and atherosclerosis progression: Unresolved questions
38. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)
39. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
40. Effects of a combina tion of β-carotene and vitamin A on lung cancer and cardiovascular disease
41. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
42. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
43. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
44. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion
45. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis
46. Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: Role of thrombin in atherosclerosis and restenosis
47. Induction of vascular cell adhesion molecule-1 by low-density lipoprotein
48. Function and activation of NK-κB in the immune system
49. Role of nuclear factor-kappa B in atherogenesis
50. Pathogenesis of atherosclerosis
51. Apolipoprotein B retention in the grossly normal and atherosclerotic human aorta
52. Low density lipoprotein concentration in interstitial fluid from human atherosderotic lesions. Relation to theories of endothelial damage and lipoprotein binding
53. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries
54. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions
55. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction
56. Low density lipoproteins bind more to type I and II collagens by negative charge-dependent mechanisms than to type IV and V collagens
57. The response to retention hypothesis of early atherogenesis
58. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit
59. The lipid-rich core region of human atherosclerotic fibrous plaques: Prevalence of small lipid droplets and vesicles by electron microscopy
60. Prelesional events in atherosclerosis: Colocalization of apolipoprotein B, unesterified cholesterol and extracellular phospholipid liposomes in the hyperlipidemic rabbit aorta
61. Cellular cholesteryl ester accumulation induced by free cholesterol-rich lipid dispersions
62. Excess membrane cholesterol alters calcium channel activity in smooth muscle of rabbit carotid arteries
63. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells
64. Enhanced synthesis and accumulation of proteoglycans in cholesterol-enriched arterial smooth muscle cells
65. Atherosclerosis alters composition, structure and function of arterial smooth muscle plasma membranes
66. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts
67. Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis
68. Membrane microdomains and caveolae
69. Cholesterol, calcium and atherogenesis
70. 2+ movements and vasoconstriction in atherosclerotic aorta
71. Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxide
72. Cholesterol-induced changes in arterial sensitivity to adrenergic stimulation
73. Oxidative stress leads to cholesterol accumulation in vascular smooth muscle cells
74. Restoration of membrane structure, composition and function in atherosclerosis arterial smooth muscle cells by human HDL
75. The actions of the charged dihydropyridine amlodipine (Norvasc) in a cell culture model of dietary atherosclerosis
76. 2+ channel blockers to the membrane lipid bilayer
77. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture
78. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix
79. Experimental models to study the prevention of atherosclerosis by calcium antagonists
80. Limits of lipid-lowering therapy: The benefits of amlodipine as an anti-atherogenic agent
81. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
82. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993
83. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
84. The role of carotid intima-media thickness in predicting clinical coronary events
85. Effect of amlodipine on progression of carotid atherosclerosis in patients with documented heart disease